QAMZOVA 30 mg/mL
Meloxicam · INJECTION · Nanjing Delova Biotech Co., Ltd.
QAMZOVA is a injection containing meloxicam at 30 mg/mL, taken intravenous. Manufactured by Nanjing Delova Biotech Co., Ltd..
Key Facts
- Brand Name
- QAMZOVA
- Generic Name
- Meloxicam
- NDC Code (Product)
82972-001- Manufacturer
- Nanjing Delova Biotech Co., Ltd.
- Strength
- 30 mg/mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- NDA217593
- Drug Class
- Nonsteroidal Anti-inflammatory Drug [EPC]
- Marketing Start
- 10/15/2025
Recall History
No Recall HistoryFull Prescribing Information
Indications & Usage
1 INDICATIONS AND USAGE QAMZOVA is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, QAMZOVA alone is not recommended for use when rapid onset of analgesia is required. QAMZOVA contains meloxicam, which is an NSAID, and is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, QAMZOVA alone is not recommended for use when rapid onset of analgesia is required. ( 1 )
Dosage & Administration
2 DOSAGE AND ADMINISTRATION Use for the shortest duration consistent with individual patient treatment goals [ see Warnings and Precautions ( 5 ) ]. For intravenous administration only. The recommended dose of QAMZOVA is 30 mg once daily, administered by intravenous bolus injection over 15 seconds. When initiating QAMZOVA, monitor patient analgesic response. Because the median time to meaningful pain relief was 2 and 3 hours after meloxicam injection administration in two clinical studies, a non-NSAID analgesic with a rapid onset of effect may be needed, for example, upon anesthetic emergence or resolution of local or regional anesthetic blocks [ see Clinical Studies ( 14) ] . Some patients may not experience adequate analgesia for the entire 24-hour dosing interval and may require administration of a short-acting, non-NSAID, immediate-release analgesic [ see Clinical Studies ( 14 ) ]. To reduce the risk of renal toxicity, patients must be well hydrated prior to administration of QAMZOVA. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration. Should the contents appear discolored or contain particulate matter, discard the vial [ …
Contraindications
4 CONTRAINDICATIONS QAMZOVA is contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to meloxicam or any components of the drug product [ see Warnings and Precautions ( 5.7 ) ]. History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal anaphylactic-like reactions to NSAIDs have been reported in such patients [ see Warnings and Precautions ( 5.8 ) ]. In the setting of coronary artery bypass graft (CABG) surgery [ see Warnings and Precautions ( 5.1 ) ]. Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion [ see Warnings and Precautions ( 5.6 ) ]. Known hypersensitivity to meloxicam or any components of the drug product. ( 4 ) History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. ( 4 ) In the setting of coronary artery bypass graft (CABG) surgery. ( 4 ) Moderate to severe renal insufficiency patients who are at risk for renal failure due to volume depletion. ( 4 )
Drug Interactions
7 DRUG INTERACTIONS See Table 3 for clinically significant drug interactions with meloxicam. Table 3: Clinically Significant Drug Interactions with Meloxicam Drugs That Interfere with Hemostasis Clinical Impact: Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of QAMZOVA with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and Precautions ( 5.12 ) ]. Aspirin Clinical Impact: Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use o…
Adverse Reactions
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in the other sections of the labeling: Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ] GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ] Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ] Hypertension [ see Warnings and Precautions ( 5.4 ) ] Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ] Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ] Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ] Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ] Hematologic Toxicity [ see Warnings and Precautions ( 5.12 )] The most common adverse reactions (≥ 2% and greater than placebo) in controlled clinical trials include constipation, GGT increased, and anemia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Nanjing Delova Biotech Co., Ltd. at 1-844-406-8288 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be direct…
Frequently Asked Questions
What is QAMZOVA used for?
QAMZOVA contains Meloxicam. It is a injection taken intravenous. Consult your doctor for specific uses.
Is QAMZOVA a controlled substance?
QAMZOVA is not classified as a controlled substance by the DEA.
What is the generic name for QAMZOVA?
The generic name for QAMZOVA is Meloxicam. There are 12 other brand versions of Meloxicam.
What is the NDC code for QAMZOVA 30 mg/mL?
The NDC (National Drug Code) for QAMZOVA 30 mg/mL is 82972-001, listed by Nanjing Delova Biotech Co., Ltd..